Home > News > APP Announces Positive Results of Intra-Arterial ABI-007
June 4th, 2003
APP Announces Positive Results of Intra-Arterial ABI-007
At the American Society of Clinical Oncology annual meeting held in Chicago, Illinois, American Pharmaceutical Partners, Inc. said that investigators from the Insituto dei Tumori in Milan, Italy, reported on their experience in 108 patients receiving high dose ABI-007, a novel cremophor-free protein engineered nanoparticle paclitaxel, by the intra-arterial route.
Ad-REIC vaccine: A magic bullet for cancer treatment September 30th, 2014
New Topical Hemostatic Agent: Neutral Self-Assembling Peptide Hydrogel September 30th, 2014
A Heartbeat Away? Hybrid "Patch" Could Replace Transplants: TAU researcher harnesses gold nanoparticles to engineer novel biocompatible cardiac patch September 30th, 2014
How things coil: Researchers discover that simulation technology designed for Hollywood can be used as a predictive tool for understanding fundamental engineering problems September 29th, 2014